Yu Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yu Song has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Binbin Zhang
Department of Translational Medicine Platform, The Affiliated Hospital of Hangzhou Normal University
1 shared publicationDandan Peng
Department of Translational Medicine Platform, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
1 shared publication- Jianan Zhao
Department of Cardiovascular Sciences,Temple University, Philadelphia, PA, USA
1 shared publication - Junping Shi
Department of Liver Diseases, Hangzhou Normal University Affiliated Hospital, Hangzhou, Zhejiang, China
1 shared publication Kaiyuan Zhang
College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China
1 shared publicationMinjie Jiang
Department of Translational Medicine Platform, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
1 shared publication
Latest Publications
- Open Access
- 26 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1942618
From mucosal activity to medicinal products: translational evidence for Akkermansia muciniphila extracellular vesicles
Akkermansia muciniphila extracellular vesicles (AKK-EVs) are being investigated as cell-free treatments for intestinal and metabolic disease, but their therapeutic value depends on what they add beyond whole bacteria, purified microbial components, or alternative carriers. This critical narrative review examines 50 publications available up to 19 July 2026, distinguishing vesicle interventions from studies of associated proteins, whole bacteria, and engineered products. Study-level extraction and domain-based appraisal support the comparison of these preparations. The synthesis addresses product identity, causal attribution, exposure, and therapeutic comparison. Native preparations show activity in epithelial and colitis models, while metabolic findings vary with the preparation and experimental setting. For mucosal disease, the therapeutic aim is sustained functional recovery after disease onset. For liver disease, development depends on establishing whether hepatic benefit persists beyond changes in food intake or body weight and whether it results from intestinal activity or delivery to hepatic cells. Engineered products require evidence that the vesicle carrier improves payload delivery or therapeutic index. Whole-cell human trials and observational measurements of EV-associated proteins provide a clinical basis for comparison, but neither establishes the efficacy or safety of administering isolated AKK-EVs to patients. The evidence supports indication-specific preclinical investigation rather than clinical use. Progression towards human studies requires reproducible batches, disease-relevant functional benefit, route-specific repeat-dose safety, and an advantage over a justified active comparator.
- 26 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1942618
Open AccessFrom mucosal activity to medicinal products: translational evidence for Akkermansia muciniphila extracellular vesicles
Akkermansia muciniphila extracellular vesicles (AKK-EVs) are being investigated as cell-free treatments for intestinal and metabolic disease, but their therapeutic value depends on what they add beyond whole bacteria, purified microbial components, or alternative carriers. This critical narrative review examines 50 publications available up to 19 July 2026, distinguishing vesicle interventions from studies of associated proteins, whole bacteria, and engineered products. Study-level extraction and domain-based appraisal support the comparison of these preparations. The synthesis addresses product identity, causal attribution, exposure, and therapeutic comparison. Native preparations show activity in epithelial and colitis models, while metabolic findings vary with the preparation and experimental setting. For mucosal disease, the therapeutic aim is sustained functional recovery after disease onset. For liver disease, development depends on establishing whether hepatic benefit persists beyond changes in food intake or body weight and whether it results from intestinal activity or delivery to hepatic cells. Engineered products require evidence that the vesicle carrier improves payload delivery or therapeutic index. Whole-cell human trials and observational measurements of EV-associated proteins provide a clinical basis for comparison, but neither establishes the efficacy or safety of administering isolated AKK-EVs to patients. The evidence supports indication-specific preclinical investigation rather than clinical use. Progression towards human studies requires reproducible batches, disease-relevant functional benefit, route-specific repeat-dose safety, and an advantage over a justified active comparator.
- Open Access
- 11 May 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 893617
The Potential Role of Gut Microbial-Derived Exosomes in Metabolic-Associated Fatty Liver Disease: Implications for Treatment
The prevalence and incidence of metabolic-associated fatty liver disease (MAFLD), a clinically heterogeneous disease whose primary clinical therapies include dietary control and exercise therapy, is increasing worldwide and constitutes a significant medical burden. Gut microbes influence the physiopathological processes of the liver through different mechanisms based on the gut-liver axis. Exosomes are essential carriers of intercellular communication. Most previous studies have focused on adipocyte- and hepatocyte-derived exosomes, while the critical role of microbial-derived exosomes and the molecular mechanisms behind them in MAFLD have received little attention. Therefore, we searched and screened the latest relevant studies in the PubMeb database to elucidate the link between microbial-derived exosomes and the pathogenesis of MAFLD, mainly in terms of insulin resistance, intestinal barrier, inflammatory response, lipid metabolism, and liver fibrosis. The aim was to provide a theoretical framework and support for clinical protocols and innovative drug development.
- 11 May 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 893617
Open AccessThe Potential Role of Gut Microbial-Derived Exosomes in Metabolic-Associated Fatty Liver Disease: Implications for Treatment
The prevalence and incidence of metabolic-associated fatty liver disease (MAFLD), a clinically heterogeneous disease whose primary clinical therapies include dietary control and exercise therapy, is increasing worldwide and constitutes a significant medical burden. Gut microbes influence the physiopathological processes of the liver through different mechanisms based on the gut-liver axis. Exosomes are essential carriers of intercellular communication. Most previous studies have focused on adipocyte- and hepatocyte-derived exosomes, while the critical role of microbial-derived exosomes and the molecular mechanisms behind them in MAFLD have received little attention. Therefore, we searched and screened the latest relevant studies in the PubMeb database to elucidate the link between microbial-derived exosomes and the pathogenesis of MAFLD, mainly in terms of insulin resistance, intestinal barrier, inflammatory response, lipid metabolism, and liver fibrosis. The aim was to provide a theoretical framework and support for clinical protocols and innovative drug development.